🕒 Last update: loading…

Stock iRhythm Technologies, Inc. IRTC

iRhythm Technologies, Inc. — Investlytic score 2/5 on the five criteria.

-
-
40/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 2/5 criteria met.

  • ✅ Price trend passed
  • ⚠️ Mixed growth
  • ❌ Debt failed
  • ❌ P/E failed
  • ✅ Correction passed

Price trend

Overall trend (8 years): the price has been multiplied by at least 1.5.

Price change 2018 → 2019: -2.00%

Price change 2019 → 2020: 248.38%

Price change 2020 → 2021: -50.39%

Price change 2021 → 2022: -20.41%

Price change 2022 → 2023: 14.27%

Price change 2023 → 2024: -15.76%

Price change 2024 → 2025: 96.78%

Price change 2025 → 2026: -37.42%

Price change 2026 (year to date): -36.62%

Financial growth

Revenue CAGR (8 years): 26.11%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 4.79

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -256.67

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 14.02% from the high over 6 months.

Correction between 10.0% and 20.0% (target range).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
iRhythm Technologies, Inc.–4.79+38.2 %🔒
Virbac S.A.20.00.26+6.5 %★ 4/5
Carl Zeiss Meditec AG23.10.29+8.3 %–
Pediatrix Medical Group, Inc.14.00.76+2.1 %–
Addus HomeCare Corporation18.60.19+11.7 %★ 4/5

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by iRhythm Technologies, Inc. over the latest fiscal years.

Revenue
747 m USD
fiscal year 2025
Net income
-44.6 m USD
fiscal year 2025
Net margin
-6.0 %
fiscal year 2025
Average annual growth
+23.0 %
Revenue growth over 5 years
Average annual growth
+35.4 %
Revenue growth over 10 years
Market cap
3.1 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
2020265 m-43.8 m-16.5 %n/a
2021323 m-101 m-31.4 %+21.7 %
2022411 m-116 m-28.3 %+27.3 %
2023493 m-123 m-25.1 %+19.9 %
2024592 m-113 m-19.1 %+20.1 %
2025747 m-44.6 m-6.0 %+26.2 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by iRhythm Technologies, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
2.15
gray zone (1.81 to 2.99)
Piotroski Score
4 / 9
4 to 6: average accounts
DCF Value
78.06 USD
DCF close to share price · share price 94.37 USD, gap -17.3 %
Net Debt / EBITDA
362.56 x
high debt
Fiscal year20212022202320242025
Cash and investments239 m213 m134 m536 m584 m
Total Debt118 m131 m130 m737 m731 m
Net Debt-9.9 m52.2 m93.7 m317 m495 m
Equity280 m240 m210 m90.9 m153 m
Total assets463 m448 m433 m931 m1.0 bn
Operating cash flow-37.8 m-23.0 m-50.1 m3.4 m80.9 m
Investments (capex)28.1 m29.8 m40.4 m33.9 m46.3 m
Free cash-flow-65.8 m-52.8 m-90.5 m-45.6 m34.5 m
Share buybacks00025.0 m0
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-79.97 x
Price / book value17.49 x
Return on Equity (ROE)-22.8 %
Return on Invested Capital (ROIC)-4.2 %
Net margin-4.5 %
Debt / equity4.10 x
Current ratio3.57 x
Interest coverage-2.89 x
Free cash-flow yield0.2 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

Valuation and competitors

iRhythm Technologies, Inc. compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
iRhythm Technologies, Inc.3.0 bnn/a-6.0 %
HeartSciences Inc. HSCS14.1 mn/a-201,499.5 %
KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS1.7 bnn/a-190.3 %
HeartBeam, Inc. BEAT22.7 mn/a0.0 %
Medtronic plc MDT130 bn18.413.9 %
Boston Scientific Corporation BSX62.0 bn13.814.4 %
LivaNova PLC LIVN5.0 bn21.4-17.5 %
Penumbra, Inc. PEN12.6 bn83.312.7 %
AtriCure, Inc. ATRC3.0 bn1,818.0-2.1 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering iRhythm Technologies, Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
23 analysts
Average price target
174.75 USD
from n/a to n/a, 28 targets over 12 months
Gap with the share price
+93.7 %
price 90.22 USD on 06/11/2026

Breakdown of ratings

strong buy 0buy 19hold 4sell 0strong sell 0

Analysts' average target 174.75 USD, DCF value 78.06 USD, share price 90.22 USD.

Average target over the last 3 months: 174.75 USD (4 targets).

Track record against expectations: reported EPS above consensus 8 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in iRhythm Technologies, Inc.

Free float
93.7 %
share of freely traded shares
Large funds tracked
21
hold the stock as of 2026Q2
Executives (insiders)
0 / 9
0 purchases, 9 sales in 130 days

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
Vanguard Group3.3 m587 m0.0 %+2.2 %2025Q4
BlackRock3.0 m355 m0.0 %+8.9 %2026Q2
State Street1.7 m204 m0.0 %+117.3 %2026Q2
Millennium Management1.4 m167 m0.1 %-12.5 %2026Q2
Fidelity1.2 m142 m0.0 %-12.5 %2026Q2
Geode Capital Management881,899105 m0.0 %+7.9 %2026Q2
JPMorgan Chase766,21690.9 m0.0 %+7.2 %2026Q2
D. E. Shaw & Co629,68674.9 m0.1 %+13.6 %2026Q2

Latest insider transactions

DatePersonSideAmount
02/09/2026Wilson Daniel G.sale94,175 USD
10/08/2026Blackford Quentin S.sale3.3 m USD
10/08/2026Murphy Patrick Michaelsale884,156 USD
10/08/2026Patterson Chadsale884,170 USD
10/08/2026Shrishrimal Sumisale669,641 USD
10/08/2026Turakhia Minangsale884,151 USD

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 16/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 20/10/2016
ISIN code
US4500561067
Workforce
2,000
full-time employees
Chief executive
Quentin S. Blackford

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about iRhythm Technologies, Inc.

What is the iRhythm Technologies, Inc. share price?

Latest recorded price: 91.91 USD on 13/11/2026, for a market cap of 3.1 bn USD.

What is the revenue of iRhythm Technologies, Inc.?

747 m USD for fiscal year 2025, with net income of -44.6 m USD (net margin -6.0 %).

What do analysts say about iRhythm Technologies, Inc.?

Out of 23 analysts: 19 buy or strong buy, 4 hold, 0 sell or strong sell. Average price target: 174.75 USD, i.e. +93.7 % from the share price.

Is iRhythm Technologies, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US4500561067).

How many employees does iRhythm Technologies, Inc. have?

2,000 full-time employees according to the latest published profile.

Who runs iRhythm Technologies, Inc.?

Quentin S. Blackford is the company's chief executive.

Which large funds own iRhythm Technologies, Inc.?

As of 2026Q2, among the large funds tracked: Vanguard Group, BlackRock, State Street, Millennium Management, Fidelity.

07

Similar stocks